180 related articles for article (PubMed ID: 24727330)
1. High serum level of antithymocyte globulin immediately before graft infusion is associated with a low likelihood of chronic, but not acute, graft-versus-host disease.
Chawla S; Dharmani-Khan P; Liu Y; Prokopishyn N; Amlish Munir M; Griffiths C; Khan FM; Stewart DA; Russell JA; Daly A; Storek J
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1156-62. PubMed ID: 24727330
[TBL] [Abstract][Full Text] [Related]
2. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
3. Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Long-term outcomes of a prospective randomized trial.
Chang YJ; Wang Y; Mo XD; Zhang XH; Xu LP; Yan CH; Chen H; Chen YH; Chen Y; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Cancer; 2017 Aug; 123(15):2881-2892. PubMed ID: 28301690
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of the actions of antithymocyte globulin in patients undergoing allogeneic hematopoietic cell transplantation.
Yuan J; Pei R; Su W; Cao J; Lu Y
Oncotarget; 2017 Feb; 8(7):10871-10882. PubMed ID: 28107198
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation.
Ayuk F; Diyachenko G; Zabelina T; Wolschke C; Fehse B; Bacher U; Erttmann R; Kröger N; Zander AR
Biol Blood Marrow Transplant; 2008 Aug; 14(8):913-9. PubMed ID: 18640575
[TBL] [Abstract][Full Text] [Related]
6. Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBI.
Nagler A; Labopin M; Dholaria B; Niittyvuopio R; Maertens J; Poiré X; Cornelissen J; Reményi P; Bourhis JH; Beguin Y; Malladi R; Kerre T; Schroyens W; Savani BN; Mohty M
Blood Adv; 2019 Jul; 3(13):1950-1960. PubMed ID: 31262738
[TBL] [Abstract][Full Text] [Related]
7. High rabbit-antihuman thymocyte globulin levels are associated with low likelihood of graft-vs-host disease and high likelihood of posttransplant lymphoproliferative disorder.
Podgorny PJ; Ugarte-Torres A; Liu Y; Williamson TS; Russell JA; Storek J
Biol Blood Marrow Transplant; 2010 Jul; 16(7):915-26. PubMed ID: 20226870
[TBL] [Abstract][Full Text] [Related]
8. Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant.
Salem G; Ruppert AS; Elder P; Hofmeister CC; Benson DM; Penza S; Andritsos L; Klisovic R; Vasu S; Blum W; Devine SM; Jaglowski S; Efebera YA
Leuk Lymphoma; 2015 Apr; 56(4):1058-65. PubMed ID: 25166008
[TBL] [Abstract][Full Text] [Related]
9. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis.
Russell JA; Turner AR; Larratt L; Chaudhry A; Morris D; Brown C; Quinlan D; Stewart D
Biol Blood Marrow Transplant; 2007 Mar; 13(3):299-306. PubMed ID: 17317583
[TBL] [Abstract][Full Text] [Related]
10. High lymphocyte counts before antithymocyte globulin administration predict acute graft-versus-host disease.
Shiratori S; Ohigashi H; Ara T; Yasumoto A; Goto H; Nakagawa M; Sugita J; Onozawa M; Kahata K; Endo T; Hashimoto D; Teshima T
Ann Hematol; 2021 May; 100(5):1321-1328. PubMed ID: 33215225
[TBL] [Abstract][Full Text] [Related]
11. Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies.
Malard F; Cahu X; Clavert A; Brissot E; Chevallier P; Guillaume T; Delaunay J; Ayari S; Dubruille V; Mahe B; Gastinne T; Blin N; Harousseau JL; Moreau P; Miplied N; Le Gouill S; Mohty M
Biol Blood Marrow Transplant; 2011 Nov; 17(11):1698-703. PubMed ID: 21601642
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of porcine antihuman lymphocyte globulin versus antithymocyte globulin-fresenius in an allogeneic hematopoietic cell transplantation conditioning regimen for severe aplastic anemia.
Zhang Y; Liu L; Si Y; Miao M; Qiu H; Tang X; Han Y; Fu C; Jin Z; Chen S; Sun A; Wu D
Hematology; 2021 Dec; 26(1):741-750. PubMed ID: 34555301
[TBL] [Abstract][Full Text] [Related]
13. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
Devillier R; Fürst S; El-Cheikh J; Castagna L; Harbi S; Granata A; Crocchiolo R; Oudin C; Mohty B; Bouabdallah R; Chabannon C; Stoppa AM; Charbonnier A; Broussais-Guillaumot F; Calmels B; Lemarie C; Rey J; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Mar; 20(3):370-4. PubMed ID: 24315846
[TBL] [Abstract][Full Text] [Related]
14. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP; Cornetta K; Fausel CA; Farag SS
Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925
[TBL] [Abstract][Full Text] [Related]
15. Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group.
Basara N; Baurmann H; Kolbe K; Yaman A; Labopin M; Burchardt A; Huber C; Fauser AA; Schwerdtfeger R
Bone Marrow Transplant; 2005 May; 35(10):1011-8. PubMed ID: 15821768
[TBL] [Abstract][Full Text] [Related]
16. Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases.
Crocchiolo R; Esterni B; Castagna L; Fürst S; El-Cheikh J; Devillier R; Granata A; Oudin C; Calmels B; Chabannon C; Bouabdallah R; Vey N; Blaise D
Cancer; 2013 Mar; 119(5):986-92. PubMed ID: 23096591
[TBL] [Abstract][Full Text] [Related]
17. Antithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplastic syndrome: a study from the French Society of Bone Marrow Transplantation and Cellular Therapy.
Duléry R; Mohty M; Duhamel A; Robin M; Beguin Y; Michallet M; Vigouroux S; Lioure B; Garnier A; El Cheikh J; Bulabois CE; Huynh A; Bay JO; Daguindau E; Ceballos P; Clément L; Dauriac C; Maillard N; Legrand F; Cornillon J; Guillerm G; François S; Lapusan S; Chevallier P; Damaj G; Yakoub-Agha I
Biol Blood Marrow Transplant; 2014 May; 20(5):646-54. PubMed ID: 24462982
[TBL] [Abstract][Full Text] [Related]
18. Multicenter experience using total lymphoid irradiation and antithymocyte globulin as conditioning for allografting in hematological malignancies.
Messina G; Giaccone L; Festuccia M; Irrera G; Scortechini I; Sorasio R; Gigli F; Passera R; Cavattoni I; Filippi AR; Schianca FC; Pini M; Risitano AM; Selleri C; Levis A; Mordini N; Gallamini A; Pastano R; Casini M; Aglietta M; Montanari M; Console G; Boccadoro M; Ricardi U; Bruno B;
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1600-7. PubMed ID: 22484666
[TBL] [Abstract][Full Text] [Related]
19. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
Finke J; Bethge WA; Schmoor C; Ottinger HD; Stelljes M; Zander AR; Volin L; Ruutu T; Heim DA; Schwerdtfeger R; Kolbe K; Mayer J; Maertens JA; Linkesch W; Holler E; Koza V; Bornhäuser M; Einsele H; Kolb HJ; Bertz H; Egger M; Grishina O; Socié G;
Lancet Oncol; 2009 Sep; 10(9):855-64. PubMed ID: 19695955
[TBL] [Abstract][Full Text] [Related]
20. A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors.
Remberger M; Ringdén O; Hägglund H; Svahn BM; Ljungman P; Uhlin M; Mattsson J
Clin Transplant; 2013; 27(4):E368-74. PubMed ID: 23701240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
